levels of fibrinogen are a risk factor for thrombotic disease and have been observed during acute-phase reactions, pregnancy, oral contraception use, menopause, malignancies, chronic inflammatory diseases and in people who smoke. 1, [4] [5] [6] [7] [8] [9] Low fibrinogen levels can occur during acute or chronic liver disease, disseminated intravascular coagulation (DIC), thrombolytic therapy, haemodilution and consumption coagulopathy. [9] [10] [11] Thrombin time tests can be used to investigate possible bleeding disorders or the occurrence of thrombotic episodes. Thrombin time is prolonged by: decreased fibrinogen levels; abnormal function of fibrinogen; the presence of direct thrombin inhibitors, such as dabigatran, bivalirudin or argatroban; the presence of unfractionated heparin; the presence of aprotinin; and the presence of fibrinogen/fibrin degradation products and/or increased fibrinolysis (for example, due to thrombolytic therapy). 12-17 D-dimer is a very sensitive marker for the activation of coagulation. [18] [19] [20] [21] [22] [23] [24] In DIC, fibrin degradation products, such as D-dimer, can be used to confirm or refute a tentative diagnosis, estimate the potential risk for patients with existing DIC, and monitor an initiated therapy. [25] [26] [27] D-dimer levels are particularly useful to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE), and may be elevated in the presence of other causes of fibrin formation such as trauma, pregnancy complications, malignant disease or vascular abnormalities. [25] [26] [27] [28] [29] [30] High-throughput technologies designed for use in core laboratories and developed to measure fibrinogen, prothrombin time (PT)-derived fibrinogen, thrombin time and D-dimer may offer significant benefits, such as reduced error rates and increased efficiency. This multicentre study aimed to evaluate the performance of four new coagulation assays on the cobas t 711 and cobas t 511 analysers, which have been developed to measure fibrinogen, among others, PT-derived fibrinogen, thrombin time and D-dimer levels. For each assay, the analytical performance was evaluated and method comparisons with existing commercially available assays/platforms were performed. was evaluated over 5 days by measuring five aliquots of each control sample and of five human plasma samples, using the same control lots and reagent lots at all sites. Results were evaluated across the study sites.
| MATERIAL S AND ME THODS

| Study design
| Experimental procedures and data analysis
Briefly, the fibrinogen test is a Clauss assay using lyophilized bo- The full study methods, including evaluation of analytical performance, equivalency of the cobas t 711 and cobas t 511 analysers, lot-to-lot comparison, reference range evaluation, and data analysis have been described previously (for the evaluation of five other coagulation tests on the cobas t 711 and cobas t 511 analysers). 
| Reference range studies
For all assays, reference ranges were determined using anonymized residual samples (0.109M/3.2% citrate) sourced from apparently healthy adult donors at a blood bank (Freiburg, Germany). Key inclusion criteria were: 18-50 years of age, originating from Europe or the US and able to provide written informed consent; exclusion criteria were self-declared pregnancy or breast-feeding, and use of anticoagulation medication including but not limited to acetyl salicylic acid, direct oral anticoagulants, phenprocoumon, and warfarin. Samples were collected in Sarstedt tubes, and as reported previously, samples were measured fresh at the sampling site in Freiburg. All experiments were performed using three 
| RE SULTS
| Analytical performance
For each assay, the coefficients of variation (CVs) for within-run precision and total reproducibility are presented in Table 1 ; all values were within the prespecified acceptance criteria. Across all four sites and all four assays, CVs for within-run precision in human plasma samples ranged from 0.3% to 2.9% on the cobas t 711 analyser and from 0.2% to 4.1% on the cobas t 511 analyser. CVs for total reproducibility across all four sites and all four assays ranged from 1.0% to 8.6% on 
| Method comparison
The 
| Equivalency of cobas t 711 and cobas t 511 analysers
For each of the four assays evaluated, the cobas t 711 and cobas t 511 platforms demonstrated equivalence, according to prespecified acceptance criteria based on Passing-Bablok regression analyses (Table 3) . Across all four assays and sites (two sites per assay),
Pearson's correlation coefficient exceeded acceptance criteria.
Bland-Altman plots (Figures S5-S8) demonstrate constant bias for
the four assays and consistency in results for each site.
| Lot-to-lot comparison
A high level of consistency between lots was observed for all four assays on the cobas t 711 analyser (Table 4) 
| Reference range studies
| D ISCUSS I ON
Each of the four coagulation assays tested demonstrated excellent analytical performance on both the cobas t 711 and cobas t 511 analysers. Overall, the CVs for all four assays were ≤4.1% for within-run precision and ≤8.6% for total reproducibility; lot-to-lot comparisons with each assay showed a high level of consistency across all sites. two systems is in terms of throughput: the high-throughput cobas t 711 can process 390 tests/h, and the medium-throughput cobas t 511 can process 195 tests/h. The cobas t coagulation analysers offer innovative features, including high processing power and increased walkaway time for mid-to high-volume coagulation laboratories.
Connectivity, automated reagent reconstitution, and optimized reagent and sample management also provide laboratories with improved workflow and operating efficiency.
These four new coagulation assays could provide core laboratories with accurate and reliable tests for the screening, diagnosis and assessment of a range of coagulopathies in routine clinical practice.
The fibrinogen assay using the Clauss method is intended as an aid in the detection of hypo-and hyperfibrinogenaemia, dysfibrinogenaemia and afibrinogenaemia. 35, 36 The PT-derived fibrinogen assay is an alternative method for measuring fibrinogen, but may be less reliable than the Clauss method. 36 Thrombin time provides a measure of the time taken for a clot to form in plasma to which thrombin has been added, and can be used as part of an investigation into potential bleeding disorders, and/or to detect the presence of drugs that prevent conversion of fibrinogen to fibrin. 37 While the D-dimer assay is used as an aid in the exclusion of DVT/PE, it is intended to provide a fast and cost-effective test for triaging patients that present with signs and symptoms suggestive of venous thromboembolism. were included in the test samples so that the methods were evaluated at all relevant levels of analyte. This study was primarily aimed at evaluating analytical performance of the four assays and did not assess the clinical performance of the assays.
In conclusion, this multicentre study demonstrates the excellent analytical performance of four new coagulation assays on the novel cobas t 711 and cobas t 511 analysers. Each coagulation assay showed good or acceptable agreement with other commercially available assays, and the improved technologies used offer core laboratories a number of advantages over existing methods for the assessment of a range of coagulopathies in routine clinical practice.
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